Ensysce Biosciences, Inc (ENSC): Price and Financial Metrics

Ensysce Biosciences, Inc (ENSC): $0.85

0.03 (+3.99%)

POWR Rating

Component Grades








Add ENSC to Watchlist
Sign Up

Industry: Biotech




#193 of 360

in industry

ENSC Price/Volume Stats

Current price $0.85 52-week high $38.52
Prev. close $0.81 52-week low $0.77
Day low $0.79 Volume 22,402
Day high $0.85 Avg. volume 324,071
50-day MA $1.13 Dividend yield N/A
200-day MA $2.84 Market Cap 2.66M

ENSC Stock Price Chart Interactive Chart >

Ensysce Biosciences, Inc (ENSC) Company Bio

Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.

ENSC Latest News Stream

Event/Time News Detail
Loading, please wait...

ENSC Latest Social Stream

Loading social stream, please wait...

View Full ENSC Social Stream

Latest ENSC News From Around the Web

Below are the latest news stories about ENSYSCE BIOSCIENCES INC that investors may wish to consider to help them evaluate ENSC as an investment opportunity.

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

~ Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 ~~ Trial Results Expected in December 2023 ~SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ...

Yahoo | November 16, 2023

ENSC Releases Earnings and Highlights Progress

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Earnings Update • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon

Yahoo | November 10, 2023

Ensysce Biosciences Reports Third Quarter 2023 Financial Results

PF614-201 Clinical Study Results Expected by End of YearSAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription ...

Yahoo | November 9, 2023

Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

Additional Funding from Investor Cohort Validates Company's MissionSAN DIEGO, CA / ACCESSWIRE / October 24, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage company applying transformative ...

Yahoo | October 24, 2023

Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360

Poster Presentation to Showcase the Optimization Process of Ensysce's PF614-MPAR FormulationSAN DIEGO, CA / ACCESSWIRE / October 18, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative ...

Yahoo | October 18, 2023

Read More 'ENSC' Stories Here

ENSC Price Returns

1-mo -7.72%
3-mo -52.78%
6-mo -63.98%
1-year -97.56%
3-year -99.97%
5-year -100.00%
YTD -90.56%
2022 -99.20%
2021 -62.20%
2020 -94.03%
2019 6.11%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!